TITLE

Risk assessment for bleeding during warfarin therapy

PUB. DATE
December 2010
SOURCE
Internal Medicine Alert;12/15/2010, Vol. 32 Issue 23, p183
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article reports on the use of a stratification tool to assess the risk of bleeding in patients with atrial fibrillation while on warfarin therapy in the U.S.
ACCESSION #
57755150

 

Related Articles

  • Dabigatran etexilate.  // Reactions Weekly;9/21/2013, Issue 1470, p18 

    An abstract of the article "Traumatic intracranial hemorrhage in patients taking dabigatran: Report of 3 cases and review of the literature," by S. N. Wassef and colleagues is presented.

  • Dabigatran reduces heart attack, GI bleeding in real world.  // Reactions Weekly;8/10/2013, Issue 1465, p4 

    The article offers the author's insight on the role of the anticoagulants dabigatran and warfarin in heart attack and gastrointestinal (GI) bleeding. The author states that based from a study on anticoagulant-naive patients with atrial fibrillation medicated by the two agents indicate that...

  • Fatigue in a Patient with Atrial Fibrillation. Germano, Joseph J.; Steingart, Richard M. // Cortlandt Forum;8/25/2002, Vol. 15 Issue 8, p68 

    Describes a case of fatigue in a patient with atrial fibrillation. Reason for administration of amiodarone; Multiorgan side effects of amiodarone; Characteristics and physiologic effects of amiodarone.

  • The P450 system and CV outcomes with clopidogrel. Kuritzky, Louis // Internal Medicine Alert;12/15/2010 Supplement, p183 

    The article offers information on the impact of the P450 system and clopidogrel on the reduction of cardio-vascular events (CV) among people with atrial fibrillation.

  • Risk assessment for bleeding during warfarin therapy. Kuritzky, Louis // Internal Medicine Alert;12/15/2010 Supplement, p183 

    The article offers information on the role of the HAS-BLED stratification tool in evaluating one-year risk of bleeding in patients with atrial fibrillation (AF) who were undergoing warfarin therapy.

  • Rivaroxaban Tablets (Xarelto®). Elliott, William T.; Chan, James // Internal Medicine Alert;12/15/2011, Vol. 33 Issue 23, p181 

    The article reports that an oral factor xa inhibitor named Rivaroxaban has been approved for minimizing the risk of stroke and systemic embolism in patients suffering from atrial fibrillation (AF).

  • Verapamil in atrial fibrillation in hyperthyroidism. Dahlstrom, C.G.; Ladefoged, S.D. // British Medical Journal (Clinical Research Edition);5/30/1987, Vol. 294 Issue 6584, p1384 

    Investigates the verapamil in atrial fibrillation in hyperthyroid patients in Copenhagen, Denmark. Efficacy of verapamil; Measurement of raised hormone concentrations; Details of antiarrhythmic treatment and its effects.

  • Ours is a special community. Phoon, Colin K. L. // Cardiology in the Young;Apr2015, Vol. 25 Issue 4, p611 

    A personal narrative is presented which explores the author's experience of helping his cousin suffering from atrial fibrillation.

  • New QOF warfarin targets.  // Pulse;6/15/2011, Vol. 71 Issue 22, p8 

    The article reports that additional indicators were added to the quality and outcomes framework (QOF) by the National Institute for Health and Care Excellence that will increase the prescription of warfarin to patients with atrial fibrillation in Great Britain.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics